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(daily) or 35mg (weekly) between January 2001 and June 2002.
The ﬁrst prescription for one of these medications was consid-
ered the index prescription. Non-persistence was deﬁned as a
>30 days gap between two subsequent prescriptions. Compliance
was measured using the medication possession ratio (MPR), with
analyses conducted using both continuous and categorical deﬁ-
nitions. Outcomes were compared between daily and weekly reg-
imens. RESULTS: Of the 2905 new users identiﬁed based on 
a 6-month run-in, 31% had an index prescription for a daily
regimen, 69% for a weekly regimen. After six months, 46.7%
of women on the weekly regimen and 41.9% on the daily
regimen persisted with their therapies. At 12 months, the per-
centages were 27.7% and 18.9%. Longer persistence was thus
observed for once-weekly users (median: 146 vs. 120 days), but
the differences were not signiﬁcant. At 12 months, weekly users
had a signiﬁcantly higher MPR than daily users (53.7% vs.
46.9%, P = 0.0022). Similarly, the proportion of highly compli-
ant patients (≥80%) was 23% for the daily versus 32% for the
weekly regimen (P = 0.0025). A larger proportion of patients
starting on a weekly regimen remained on the same treatment
over time (98% vs. 42% for those still treated at 12 months).
An average of 1.15 switches per patient was observed. CON-
CLUSIONS: Although higher rates of compliance are observed
for the weekly compared to the daily regimen, compliance and
persistence rates for both regimens are suboptimal, and the social
and economic implications of such behavior are known to be
substantial.
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OBJECTIVES: To examine effect of co-payment on compliance
among patients who initiated statins within 6-months of hospi-
tal discharge for coronary heart disease (CHD). METHODS:
Medstat Marketscan Commercial and Medicare 1999–2003
databases containing inpatient admission, outpatient and phar-
macy claims were utilized for this study. The ﬁrst ﬁll date of a
prescription for statins within 6 month following CHD hospi-
talization was identiﬁed as the index date. The study sample con-
sisted of adults who had no statin use during the year prior to
the CHD hospitalization and had at least 12 months of follow-
up after the index date. Medication possession ratio (MPR) was
calculated as the ratio of total days supply for statins to total
days during 12-month follow-up. Being compliant to statins was
deﬁned as having a MPR of 80% or greater. Effect of co-payment
on compliance to statins was examined by a multiple logistic
regression, controlling for age, gender, region, year of the index
date, type of CHD, concomitant co-morbidity and concomitant
use of other medications. RESULTS: In total, 5548 patients met
the inclusion criteria and were included in the analysis. In total,
3404 (61.36%) had a MPR of 80% or over and were consid-
ered compliant to statins. Compared with those who had a co-
payment of $10 or lower, patients with a co-payment over $20
were signiﬁcantly less likely to be compliant to statins (OR, 0.46;
95% CI, 0.40–0.54). Other factors signiﬁcantly associated with
compliance in the model were age, gender, region, hyperlipi-
demia, depression, concomitant use of non-statin lipid lowering
drugs and beta-blockers, and type of CHD. CONCLUSIONS:
High co-payment (>$20) appears to be a signiﬁcant barrier to
compliance to statins, even after adjusting for demographic and
clinical variables.
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OBJECTIVE: Poor patient outcomes associated with low levels
of adherence to medication have been previously reported in
several chronic conditions. In transplantation, inadequate
immunosuppression (IS) can lead to rejection and graft loss as
well as increased healthcare costs. We evaluated patient and
regimen characteristics associated with IS adherence in a private
payer transplant population. METHODS: U.S. commercial
claims data for de novo kidney, heart, liver, lung, pancreas and
kidney-pancreas recipients transplanted 1995–2003 were linked
to data from the Organ Procurement Transplant Network, a
national transplant registry. All patients had ≥1 IS reﬁll and were
followed up to 1-year post-transplant. Patients who switched
between study drugs were excluded. Medication adherence was
measured by the medication possession ratio (MPR) i.e. ratio of
number of therapy days supplied to number of follow-up days.
The Kaplan-Meier product-limit method was used to estimate
time to non-adherence. Adherence was deﬁned as having a MPR
≥ 90% and was modeled using multivariate logistic regression.
RESULTS: In total, 349 transplant recipients met study criteria.
Mean adherence to index IS therapy was 84% (MPR = 0.84).
Mean time to non-adherence was 8.4 months. Older age (OR =
1.03, p = 0.0005) and higher number of primary care visits (OR
= 1.02, p = 0.03) were associated with higher odds of adherence.
Hispanic ethnicity (OR = 0.34, p = 0.004), more co-morbidities
(OR = 0.90, p = 0.078), less than college education (OR = 0.66,
p = 0.07), or a greater number of other prescription medications
(OR = 0.95, p = 0.03) were associated with a lower likelihood
of adherence. Copay and gender were not signiﬁcantly associ-
ated with adherence. CONCLUSIONS: The mean level of adher-
ence to immunosuppressive therapy was in congruence with
previous ﬁndings for other chronic medications. Medication reﬁll
adherence was associated with age, race, co-morbidity index,
education status, primary care visits and number of medications
taken. Drug copay did not impact adherence to immunosup-
pression therapy in this transplant population.
HP8
PATIENT CHARACTERICS, GLYCEMIC CONTROL,AND THE
USE OF ANTIDIABETIC AGENTS AMONG INDIVIDUALS
DIAGNOSED WITH TYPE-2 DIABETES: EVIDENCE FROM 
THE UK
Secnik K1,Yurgin N1, Lage MJ2, McDonald-Everett C1
1Eli Lilly and Company, Indianapolis, IN, USA; 2HealthMetrics
Outcomes Research, LLC, Groton, CT, USA
OBJECTIVES: Glycosylated hemoglobin (HbA1c) is a well-
established measure of glycemic control and evidence shows that
maintaining an acceptable HbA1c level may be associated with
lower rates of diabetic complications. Many countries have
established speciﬁc HBa1c target values indicative of good
glycemic control for patients with type-2 diabetes. This study
examined the characteristics of patients with type-2 diabetes and
investigated whether patients met the National Institute for Clin-
ical Excellence (NICE) recommended target. METHODS: Data
were obtained from the UK Mediplus Database. Patients identi-
ﬁed as having type-2 diabetes between January 1, 2004 and June
30, 2004 was included in the analysis. Co-morbidities and com-
plications were also examined. Use of antidiabetic medication
between April 1, 2004 and June 30, 2004 was reviewed. A subset
of the patients who received an HbA1c test was examined, as
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was their use of antidiabetic medications in the 90 days prior to
their HbA1c test. All results are descriptive in nature. RESULTS:
A majority of the patient population was male in their mid-60.
Hypertension (51%) and ischemic heart disease (19%) were
commonly diagnosed co-morbidities. Of patients with type-2
diabetes, 30% received no antidiabetic medications, 41% were
treated with a single antidiabetic agent (e.g., metformin, sul-
fonylurea), while the remaining patients received combination
therapy. Over half of the patients who received some antidiabetic
medication had an HbA1c that did not meet the NICE recom-
mendation of 7.5% or less. Interestingly, more than 70% of the
patients who received either insulin alone or in combination with
oral antidiabetic medications (s) had HbA1c values greater than
7.5%. CONCLUSIONS: Despite recent important advances in
pharmacotherapy for type-2 diabetes, glycemic control remains
suboptimal for a large percentage of patients in the UK. In order
to adhere to NICE recommendations, health care professionals
may wish to consider further additive or alternative treatment
options.
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OBJECTIVE: The link between clinical responses to treatment
and changes in the Dermatology Life Quality Index (DLQI) has
not been established in moderate to severe plaque psoriasis. The
objective of this study was to determine changes in DLQI total
score that correlate with clinical improvement in this patient
group treated with adalimumab. METHODS: A randomized,
double-blind, placebo-controlled, multi-center clinical trial for
the treatment of moderate to severe plaque psoriasis with adal-
imumab was conducted. Patients (n = 147) were randomized to
adalimumab 40mg every other week (eow), adalimumab 40mg
weekly, or placebo, and were followed for up to 12 weeks. The
correlation between changes in the DLQI total score and clini-
cal assessment of psoriasis severity, using the Psoriasis Area and
Severity Index (PASI), was evaluated. To determine a minimum
clinically important difference (MCID) for DLQI total score, a
change of between 25% and 49% in the PASI score was used.
Three standard distributional methods were used to determine
the MCID for DLQI total score. RESULTS: The MCID for DLQI
total score ranged from 2.3 to 4.0. This represents changes in
dermatologic functional limitations in patients who achieved at
least a 25% improvement in PASI score. In patients who had
achieved at least a 75% improvement in PASI score, mean
improvement in DLQI total score was 10.8 points in patients
randomized to adalimumab 40mg eow, 11.5 points in those who
had received adalimumab 40mg weekly, and only 1.3 points in
the placebo group. CONCLUSION: The MCID for DLQI total
score established in this study was between 2.3 to 4.0. Given that
adalimumab-treated patients experienced a mean change in
DLQI of at least 10 points, improvement in dermatologic-related
functional limitations with this treatment is likely above the
MCID.
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OBJECTIVES: Fatigue is a common, distressing symptom of
ankylosing spondylitis (AS), a chronic inﬂammatory disease pre-
dominantly affecting the spine. This study evaluated whether
adalimumab therapy reduced fatigue in patients with active AS.
METHODS: A randomized, placebo-controlled, Phase III study
of adalimumab was conducted in Canada with patients with
active AS who had experienced an inadequate response to at 
least one NSAID or disease-modifying, antirheumatic drug
(DMARD). Patients received either adalimumab 40mg every
other week or placebo for 24 weeks. Fatigue was assessed by the
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F), a widely used measure of fatigue in chronic illnesses,
and the fatigue item of the BATH AS Disease Activity Index
(BASDAI), a well-established instrument used in clinical studies
to evaluate AS disease activity. FACIT-F scores range from 0–52,
with higher scores representing less fatigue, and a >= 3-point
change considered clinical meaningful. The BASDAI fatigue item
ranges from 0–10, with lower scores reﬂecting less fatigue.
RESULTS: A total of 82 patients (38 on adalimumab, 44 on
placebo) were enrolled. At baseline, both arms had comparable
demographics and disease characteristics. Baseline FACIT-F
(adalimumab 24.4, placebo 23.6) and BASDAI fatigue (adali-
mumab 6.3, placebo 6.9,) were similar between arms. After 12
weeks, adalimumab patients had achieved statistically signiﬁ-
cantly greater improvement in FACIT-F than placebo patients
(6.9 vs. 1.7, p = 0.005). In addition, patients on adalimumab had
achieved statistically greater improvement in BASDAI fatigue vs.
placebo (-1.7 vs. -0.5, p = 0.006). Even greater improvements
were achieved at 24 weeks in adalimumab vs. placebo patients
for both measures (FACIT-F, 7.8 vs. 2.6, p = 0.013, and BASDAI
fatigue, -1.9 vs. -0.5, p = 0.006). Improvements in FACIT-F at
both 12 and 24 weeks were clinical meaningful. CONCLU-
SIONS: These results indicate adalimumab treatment provides
AS patients with statistically signiﬁcant and clinically meaning-
ful improvements in fatigue compared with placebo.
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OBJECTIVES: To describe the observed changes in quality of life
and bother associated with LUTS at one year from baseline
assessment in a sample of Italian women. METHODS: The
FLOW study is a two-year observational investigation aimed at
evaluating prevalence, clinical progression and QoL impact of
female LUTS. Women aged ≥ 18 years, not pregnant, with LUTS
for ≥3 months and negative dipstick were consecutively enrolled
in 39 Italian Urology Centres. Symptoms and QoL were assessed
by: ICIQ-LF, W-IPSS and SF-36. Differences between the ques-
tionnaires’ scores at baseline and follow-up visits were calculated
to assess deterioration or improvement in QoL. Here we refer to
